



## **Clearside Biomedical to Present at the 38th Annual J.P. Morgan Healthcare Conference**

January 6, 2020

ALPHARETTA, Ga., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the Company will present at the 38<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 16, 2020 at 11:30 a.m. PT.

A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: [Events and Presentations](#). An archive of the webcast will be available for three months.

### **About Clearside Biomedical**

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside's proprietary SCS Microinjector™ targeting the suprachoroidal space (SCS) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company's SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit [www.clearsidebio.com](http://www.clearsidebio.com).

### **Investor and Media Contacts:**

Jenny Kobin  
Remy Bernarda  
[ir@clearsidebio.com](mailto:ir@clearsidebio.com)  
(678) 430-8206

Source: Clearside Biomedical, Inc.



Source: Clearside Biomedical, Inc.